GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Tax Rate %

BMRN (Biomarin Pharmaceutical) Tax Rate % : 26.35% (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Biomarin Pharmaceutical's Tax Expense for the three months ended in Dec. 2024 was $45 Mil. Biomarin Pharmaceutical's Pre-Tax Income for the three months ended in Dec. 2024 was $170 Mil. Therefore, Biomarin Pharmaceutical's Tax Rate % for the quarter that ended in Dec. 2024 was 26.35%.

Biomarin Pharmaceutical Tax Rate % Historical Data

The historical data trend for Biomarin Pharmaceutical's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Tax Rate % Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,843.02 14.96 5.36 11.09 21.21

Biomarin Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.42 16.00 18.89 21.10 26.35

Biomarin Pharmaceutical Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Biomarin Pharmaceutical's Tax Rate % for the fiscal year that ended in Dec. 2024 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2024 )/Pre-Tax Income (A: Dec. 2024 )
=114.904/541.763
=21.21 %

Biomarin Pharmaceutical's Tax Rate % for the quarter that ended in Dec. 2024 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2024 )/Pre-Tax Income (Q: Dec. 2024 )
=44.696/169.639
=26.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical Tax Rate % Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Tax Rate %
Comparable Companies
MRNA INCY RPRX INSM EXEL TECH SRPT PCVX UTHR SMMT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
BMRN:Mexico 1BMRN:Italy 0HNC:UK BM8:Germany BM8:Germany B1MR34:Brazil BMRN:Austria
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
https://www.biomarin.com
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Executives
Erin Burkhart officer: GVP, Chief Accounting Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Charles Greg Guyer officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
George Eric Davis officer: VP, General Counsel C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Jean Jacques Bienaime director, officer: Chief Executive Officer 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Robert Ajer officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Henry J Fuchs officer: Chief Medical Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
V Bryan Lawlis director
Richard A Meier director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Dennis Slamon director 770 LINDARO STREET, SAN RAFAEL CA 94901
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612